Genmab AS (GMAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $31.80B
Last updated: Nov 17, 2026 at 4:33 PM ET
Genmab AS (GMAB) Stock Chart
Genmab AS (GMAB) has a latest price of $51.96 on Nov 17, 2026, 13.4% below its 52-week high of $59.97. Its price rose 71.7% over the past 12 months. The month-end price rose 242.2% over the 10 years through Oct 2026, a compound annual rate of 13.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $57.06 in Oct 2026 and its lowest $13.67 in Oct 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart GMAB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GMAB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 52.3%, and over 6 months it rose 102.3%. The month-end price rose 100.9% over the 3 years through Oct 2026, a compound annual rate of 26.2%.
| Period | Change |
|---|---|
| 1 month | +35.0% |
| 3 months | +52.3% |
| 6 months | +102.3% |
| 12 months | +71.7% |
| 12 months, with dividends | +71.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +100.9% | +26.2% |
| 5 years | +27.8% | +5.0% |
| 10 years | +242.2% | +13.1% |
Price by Year
Its best calendar year was 2020, when the price rose 82.1%, and its weakest was 2024, when it fell 34.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $57.06 | +85.3% |
| 2025 | $30.80 | +47.6% |
| 2024 | $20.87 | -34.5% |
| 2023 | $31.84 | -24.9% |
| 2022 | $42.38 | +7.1% |
| 2021 | $39.56 | -2.7% |
| 2020 | $40.66 | +82.1% |
| 2019 | $22.33 | +35.5% |
| 2018 | $16.48 | -0.6% |
| 2017 | $16.58 | 0.0% |
Trading Range
The price is 24.1% above its 50-day average of $41.88 and 63.8% above its 200-day average of $31.73.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $51.96 | |
| 52-week high | $59.97 | -13.4% |
| 52-week low | $23.62 | +120.0% |
| 50-day average | $41.88 | +24.1% |
| 200-day average | $31.73 | +63.8% |
Price Risk
Over 3 years, its largest fall from a peak was 45.1%.
| Measure | Value |
|---|---|
| 1-year beta | 0.89 |
| Largest fall, 1 year | -32.5% |
| Largest fall, 3 years | -45.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About GMAB
What is GMAB's 1-year price change?
Genmab AS's price rose 71.7% over the past 12 months. With dividends included, the 12-month total return was 71.7%.
What is GMAB's 5-year price change?
Genmab AS's month-end price rose 27.8% over the 5 years through Oct 2026, a compound annual rate of 5.0%. These figures leave out dividends.
What is GMAB's 52-week high and low?
Genmab AS's 52-week high is $59.97 and its 52-week low is $23.62. Its latest price of $51.96 on Nov 17, 2026 is 13.4% below the high.
What is GMAB's beta?
Genmab AS's 1-year beta against the S&P 500 is 0.89, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 32.5%.
Is the GMAB chart free?
Yes. Advanced Charting for GMAB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
GMAB pages: Overview, Charting, Statistics, Valuation, Competitors